19003 001 Global Discovery A4 6pp Pdfw


Published on

Alternative approaches to developing strategic partnerships in order to drive discovery and innovation and enhance pipelines.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

19003 001 Global Discovery A4 6pp Pdfw

  1. 1. Register and pay before 30th July and save up to £400 GLOBAL DISCOVERY OUTSOURCING AND COLLABORATIONS FORUM 2010 Two Day Conference: 20th – 21st October 2010 Pre-Conference Workshop Day: 19th October CCT Venues, Canary Wharf, London, UK Hear from 17 leading pharma Alternative approaches to developing and bio experts… www.globaldiscoverycollaborations.com Frederik Deroose,Director, Head External strategic partnerships: driving discovery, Collaborations and Outsourcing Services, Johnson & Johnson innovation and enhancing pipelines Michael Sierra, Director of External Discovery, Leo Pharma Dr Iain Comley, Associate Director, Key reasons to attend: Science & Technology Alliances, AstraZeneca ® aximise profitability through strategic and tactical partnerships and examine M Dr Stephen Shuttleworth, CSO, a range of partner selection processes with GlaxoSmithKline, Novartis Karus Therapeutics and Merck Dr Zoran Rankovic, Associate Director, Medicinal Chemistry, Investigate the varying scales of partnerships in emerging markets and ® Merck UK assess long term strategies for working in Asia with discussions from AstraZeneca Pascal Touchon, Director, Facilitate access to innovative technologies and high level expertise: ® Head of Scientific Collaboration & Business Development, where is there room for innovation in your business model? Case studies Servier and discussions from Nycomed and Symphogen Patrice Talaga, Director Chemistry Outsourcing, Establish early alliance and risk sharing collaborations and examine the ® UCB Mathias Schmidt, Associate Principal, licensing considerations with the latest developments from Bristol-Myers Head of Early Alliance Team, Squibb and UCB. Get the Nycomed academic’s perspective from Imperial College London Drug Discovery Unit Hansjoerg Lehmann, Lab Head, Preparation Laboratories, ® iscuss the most effective outsourcing and collaboration strategies to D Novartis ensure your partner meets the needs of your company and drives the pipeline Jorge Beleta, Director Discovery Strategy, forward. Hear the latest strategies from Novartis, Novo Nordisk and Leo Pharma Almirall Promote growth and innovation through implementing a virtual Pharma ® Dr Catherine Tralau, Head of Drug Discovery Facility& Pharmacology, model with case studies from Poxel and Karus Therapeutics. Imperial College London Jayshree Mistry, Outsourcing Associate, GlaxoSmithKline Pre-Conference Workshop Day Lubor Gaal, Head of Europe, Plus an interactive preconference workshop day addressing the set up and Strategic Transactions Group, management of early alliances, key strategies for effective relationship management. Bristol Myers-Squibb Hear case studies from Novartis, GlaxoSmithKline and Merck Søren Bregenholt, COO and Head Preclinical R&D, Symphogen Sophie Hallakou-Bozec, Research Director and Cofounder, Poxel Johan Weigelt, Zoran Rankovic, Mathias Schmidt, Hansjeorg Lehmann, Chief Scientist, Associate Director Associate Principal, Lab Head, Structural Genomics Consortium Medicinal Chemistry, Head Early Alliance Team, Preparation Laboratories, Tomas Landh, Merck UK Nycomed Novartis Director of Strategy and Sourcing, Novo Nordisk Telephone: Fax: Email: Visit: +44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globaldiscoverycollaborations.com
  2. 2. SPONSORS AND EXHIBITORS Who will attend? Directors, senior managers and managers within pharmaceutical manufacturers, biotech companies and academic institutes with responsibility for: • Discovery Outsourcing • Business Development • R&D • Chemistry • Externalisation • Alliances • Discovery Strategy • Strategic Partnerships Why Attend? Explore the varying scales of partnerships and business models to drive innovation, access the latest expertise and technologies and enhance pipelines. Maximise Your Involvement: Sponsorship and Exhibition Opportunities About Pharma IQ The Pharma IQ Global Discovery Outsourcing and Collaborations Forum Web: www.pharma-iq.com Phone: +44 (0) 207 368 9300 will be the perfect platform for service providers to meet senior-level Become a member of Pharma IQ and receive complimentary access to decision makers in the pharmaceutical/biopharmaceutical industry resources that will keep you at the forefront of industry change. You will implementing specific drug discovery solutions and services. receive access to our growing library of multi-media presentations from Contact Pharma IQ to discuss how to position your company in front to industry leaders, an email newsletter updating you on new content that your participants who are keen to learn more about today’s technologies has been added, free aggregated news feed from over 1000 global news and services including: Leo Pharma, Almirall, Nycomed, UCB, Bristol sources tracking your industry and special member only discounts Myers-Squibb and many more. on events. Become a member here: www.pharmaceuticaliq.com/ ‘Very valuable, learned a lot, inspired.’ Novartis Pharma Media Partners: Telephone: Fax: Email: Visit: +44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globaldiscoverycollaborations.com
  3. 3. Pre-Conference Workshop Day. Tuesday 19th October 2010 Examining Various Business Models to Achieve the Optimum Partnership and Maximise Profitability 10.30 – 13.30 WORKSHOP A: Enhancing Efficiency and Productivity in Lead Discovery This interactive workshop will give attendees the platform to discuss lead discovery and optimisation process, as well as the outsourcing considerations during these processes to ensure efficiency and profitability. You will walk away from this workshop with new ideas on: • Understanding the hit to lead process in the context of drug discovery • What to outsource and how to find a suitable CRO/partner • Effective hit generation strategies • Hit selection – defining the selection criteria and decision making process • Hit optimisation; assessing risks and addressing deficiencies • Medicinal chemistry strategies and tips to improve hERG selectivity and ADME properties Facilitator: Dr Zoran Rankovic, Associate Director, Medicinal Chemistry, Merck UK 14.30 – 17.30 WORKSHOP B: Setting Up and Effectively Managing Early Alliances By attending this hands on workshop attendees will gain in depth insights into the practical approaches of setting up early alliances and strategies to maximise internal and external resources in a bid to drive discovery. In this workshop you will walk away with new initiatives on: • How to implement an early alliance effectively • An overview of the internal and external opportunities • Interacting with your partner to understand expectations and ensure a successful partnership • Case studies Facilitator: Mathias Schmidt, Associate Principal, Head of Early Alliance Team, Nycomed OR 14.30 – 17.30 WORKSHOP C: Achieving an Effective Working Relationship with your Partner to Ensure a Successful a Profitable Collaboration This hands on workshop will enable participants to understand the long term considerations of a collaboration and solutions to effectively manage expectations and ensure a successful partnership From this workshop attendees will gain a fresh perspective on: • Ensuring reliability of quality and timing from your partner • Assessing the long-term benefits of an winning partnership, not just the short-term cost savings • Establishing flexibility regarding reporting and communications with providers from emerging markets Facilitator: Hansjoerg Lehmann, Lab Head, Preparation Laboratories, Novartis ‘Great mix of presenters covering a comprehensive range of topics-well done. Superb networking opportunity.’ Pfizer Telephone: Fax: Email: Visit: +44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globaldiscoverycollaborations.com
  4. 4. Conference Day One. Wednesday 20th October 2010 08.15 Registration and Coffee 12.40 Early Alliances and Risk Sharing Portfolios: An Academic’s Perspective 08.50 Pharma IQ’s Welcome and Opening Remarks from Chairperson CASE • The growth of robust drug discovery models within academia Pascal Touchon, STUDY Director, Head of Scientific Collaboration • The academic virtual biotech model within Imperial and why it is such an efficient option & Business Development, Servier • The importance of early phase collaborations to deliver pharma’s future pipeline • Challenging the traditional Pharma drug discovery model Dr Catherine Tralau, Understanding the Varying Scales of Partnerships Head of Drug Discovery Facility & Pharmacology, and Collaborations and Implementing the Right Imperial College London Business Model to Suit Your Needs 13.20 Networking Lunch 09.00 Optimising Your Business Model: Outsourcing vs. Collaboration 14.50 Breakout Roundtable Discussions • Assessing the spectrum of collaboration with external partners to enhance access to scientific and technological resources Participants will be able to choose one of the roundtables outlined below and • Saving time and cost through outsourcing combined processes spend 45 minutes discussing the points before feeding back to the group. • Maximising external resources by implementing varying partnership models • Identifying potential partners and understanding the differences when working Roundtable A: with a private company and with academia CASE • Where is there room for innovation in your business model? STUDY Global Licensing Strategies Tomas Landh, • Assessing the opportunities and establishing strategic deals to drive innovation Director Strategy and Sourcing, • Identifying new licensing prospects that will close gaps in therapeutic areas Novo Nordisk • Case studies and experiences of effective licensing partnerships Lubor Gaal, 09.40 Sharing Intellectual Property and Working in Intellectual Head of Europe, Strategic Transactions Group, Tandem to Improve Innovation and Drug Development Bristol Myers-Squibb • Choosing the scale of input from your partner and structuring the agreements accordingly • An overview of licensing options and ensuring the a mutually beneficial deal Roundtable B: • Establishing IP ownership deals that provide mutual benefit CASE Risk Sharing Partnerships: Understanding the Long • Combining problem solving and intellectual sharing with external partners to drive STUDY Term Value drug discovery and speed time to market • Exploring the degrees of collaboration with CROs: what can your CRO offer you Soren Bregenholt, in terms of intellectual input? COO, Jorge Beleta, Symphogen Director Discovery Strategy, Almirall 10.20 CRO SPOTLIGHT SESSION 15.30 Public Private Partnerships – A Working Model for Open This session will be dedicated to a leading service provider within the drug Innovation discovery field, offering you the opportunity to hear first hand how the latest CASE • An overview of collaborative models innovations can help you reach your drug development goals. STUDY • The pre-competitive boundary • Protein family based chemical biology • Tools for target validation 10.50 Networking Coffee Break Johan Weigelt, 11.20 Open Innovation and Risk Sharing Partnerships – Chief Scientist, What are the Benefits and Practicalities? Structural Genomics Consortium CASE STUDY • An overview of open innovation and the set up practicalities • Finding new, innovative models to replenish the pipeline 16.10 Networking Refreshment Break • Operational excellence and open innovation: are they compatible? • Successful Open Innovation: what matters? Patrice Talaga, Implementing Varying Licensing Partnerships to Director Chemistry Outsourcing, Fill IP Gaps UCB 12.00 Driving Innovation through Early Alliances and Understanding 16.40 Clarifying the Contractual and Legal Landscapes of the Practical and Relationship Management Implications Early Alliances CASE • Case studies and experiences of effective licensing partnerships • Brief overview about the standing of biologics in the pharma industry – why can STUDY pharma NOT afford to neglect biologics • An overview of various types of partnerships in early stages of drug discovery • Implementing a biologics strategy into a pharma company with a traditional focus • Moving from strategic research alliance to licensing on small molecule drugs rather than biologics • Key issues linked with partners capabilities • Expanding the biologics portfolio through forming early alliances – a win-win • Managing the IP portfolio over the long term situation that circumvents the implementation of complicated and sophisticated • Building the right foundations for long term partnership in the contract technology platforms in-house Pascal Touchon, • Assessing the needs and motivations of your partner and the importance of Director, Head of Scientific Collaboration matching them with your own & Business Development, Servier Mathias Schmidt, Associate Principal, Head of Early Alliance Team, Nycomed 17.20 Closing Remarks from Chairperson and End of Day Two Telephone: Fax: Email: Visit: +44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globaldiscoverycollaborations.com
  5. 5. Conference Day Two. Thursday 21st October 2010 08.15 Registration and Coffee 12.10 Effectively Matching Your Requirements to CRO Capabilities 09.00 Pharma IQ’s Welcome and Opening Remarks from Chairperson to Drive Productivity and Enhance Value Sophie Hallakou-Bozec, • An overview of the what can be outsourced during the discovery process Research Director and Cofounder, • Improving value and cost-effectiveness through prioritising your outsourcing Poxel • Outsourcing part or all of the discovery process: what are the benefits and considerations? Maximising Partnership Productivity Through • Matching the capabilities of CROs to your specific needs to ensure access Effective Identification, Selection and Relationship to high quality expertise and technologies Michael Sierra, Management Director of External Discovery, 09.10 Successfully Driving Drug Discovery and Development Leo Pharma CASE through Establishing a Virtual Pharmaceutical Model STUDY • Rationale for a virtual R&D model 12.50 Networking Lunch • Key criteria to assess and collaborate with potential partners • Implementation and management of the partnership: leveraging the success 14.20 Ensuring a High Return on Investment for All Discovery of the collaboration Partnerships • Maximising profitability and productivity throughout the discovery and • Understanding the variability of outsourcing quality for different processes development process • Tracking the cumulative costs of outsourcing as a whole to determine the overall Sophie Hallakou-Bozec, costs and ROI Research Director and Cofounder, • Assessing your internal resources to make tactical partnering decisions Poxel • Getting value for money at all service levels 09.50 Targeted Small Molecule Lead Discovery, Optimisation • Negotiation strategies to ensure a fair deal at the earliest stage Frederik Deroose, and Development in a Semi-Virtual R&D Environment CASE Director, Head External Collaborations STUDY • Creating and developing a unique scientific angle, building the right internal team and Outsourcing Services, Johnson & Johnson of experimentalists, identifying CROs with specific strengths in the lead discovery, development and optimisation process • Establishing the right balance between internally-conducted versus externally- Driving Efficiency and Cost Reductions through sourced chemistry and in vitro and in vivo biology, pharmacology and toxicology • Identifying key academic collaborators on translational research Strategic Outsourcing to Emerging Markets • Case histories outlining the discovery and development of novel PI3K-p110beta/ delta dual inhibitors for the treatment of immune-inflammatory diseases, and 15.00 Outsourcing in Discovery Chemistry: Strategy, Selection, Success • Identifying your needs to establishing a suitable business model on HDAC6-selective inhibitors for the treatment of inflammation, cancer and CASE • Selection process: identifying the optimum business partner (CRO) neurodenegeration Y STUD • Improving and fostering an efficient collaboration Dr Stephen Shuttleworth, • Successfully managing outsourcing projects CSO, • Effective approaches to troubleshooting Karus Therapeutics • Monitoring of key success determinants Hansjoerg Lehmann, 10.30 Networking Refreshment Break Lab Head, Preparation Laboratories, 11.00 Interactive Cross Sector Panel: Novartis Early Alliance Partnerships Between Academia and Pharma • Pharma’s strive for operational excellence and examples of breakthroughs type 15.40 Networking Refreshment Break of research collaborations • Common misperceptions from academia: aligning scientific mechanisms and Practical Approaches to Virtual Pharma: Ensure medical utilities and the need to match the expectations of all partners • Common misperceptions in pharma: working together to develop underlying Success through Efficient Set Up and Management science and valuable therapeutics of Partnerships • THE SOLUTION – Trying to Speak the Same Language: Creating a common understanding of both, academia’s and pharma’s capabilities and capacities 16.10 Outsourcing Chemistry: Finding the Right Partner for the • Funding options to facilitate early industry-academic collaborations and deliver CASE Right Job the required industry outcome STUDY • Data sets for the transition from preclinical to clinical testing Dr Catherine Tralau, Head of Drug Discovery Facility & Pharmacology, • What and where to outsource Imperial College London • Choosing the right partner and most suitable business model Patrice Talaga, Director Chemistry Outsourcing, UCB • Managing collaboration and key performance indicators Mathias Schmidt, Associate Principal, Head of Early Alliance Team, Nycomed • Case studies Dr Zoran Rankovic, Understanding the Real Cost of Outsourcing and Associate Director, Medicinal Chemistry, Merck UK Ensuring Value throughout the Whole Discovery Process 11.30 Creating Collaborative and Risk Sharing Partnerships in 09.10 Establishing Optimum Selection Criteria to Enhance the CRO Emerging Markets Selection Process • The advancement of business models available in the Asian market with the • Identifying your needs and applying an appropriate business model to get the move from traditional outsourcing to collaborations and risk sharing most out of your partners • Taking an alternative approach to partnering with CROs in Asia and gaining access • Assessing the track record and capabilities of CROs to high quality technology and expertise • Implementing pilot studies to directly assess several partners simultaneously • Obtaining insight into the levels of training and scientific knowledge outside and taking a comparative approach Western Europe as a key decider in the type of partnership • Using internal expertise to interpret quality of pilot study data and assess consistency • Understanding cultural differences and establishing effective communication Jayshree Mistry, to ensure a successful collaboration Outsourcing Associate, Dr Iain Comley, GlaxoSmithKline Associate Director, Science & Technology Alliances, AstraZeneca 17.20 Closing Remarks from Chairperson and End of Day One Telephone: Fax: Email: Visit: +44 (0)20 7368 9300 +44 (0)20 7368 9301 enquire@iqpc.co.uk www.globaldiscoverycollaborations.com
  6. 6. GLOBAL DISCOVERY OUTSOURCING 5 easy ways to register AND COLLABORATIONS Web www.globaldiscoverycollaborations.com FORUM 2010 Two Day Conference: 20th – 21st October 2010 Phone +44 (0) 20 7368 9300 Pre-Conference Workshop Day: 19th October CCT Venues, Canary Wharf, London, UK Fax +44 (0) 20 7368 9301 REGISTRATION FORM To speed registration, please provide the priority code located on the mailing label or in the box below. Email enquire@iqpc.co.uk My registration code is PDFW Post IQPC Ltd. Anchor House, Please contact our database manager on +44(0) 207 368 9300 or at database@iqpc.co.uk quoting the registration code above to inform us of any changes or to remove your details. 15-19 Britten Street, London SW3 3QL TEAM DISCOUNTS IQPC recognises the value of learning in teams. Groups of 3 or more booking at the same time from the same company receive a 10% discount. 5 or more receive a 15% discount. 7 receive a 20% discount. Only one discount available per person. Team discounts are not applicable in conjunction with another discount. Delegate Rates FREE ONLINE RESOURCE Our website has changed! You will now find a variety of resources Book and Pay Book and Pay Package Before 30th July*** Before 3rd September*** Standard Price such as articles, news, podcasts and presentations available online. Many of these features are exclusive to IQPC so visit www.globaldiscoverycollaborations.com today and learn something Conference + 2 Workshops ** Save £400 Save £300 new for free. + Full access to c £2596 + VAT c £2696 + VAT c £2996 + VAT Conference Recordings * Conference + Two Workshops ** Save £300 c £2197 + VAT Save £200 c £2297 + VAT c £2497 + VAT VENUE INFORMATION Venue: CCT Venues – Canary Wharf, Isis Building, Thames quay, 193 Marsh Wall, London, E14 9SG Conference + 1 Workshop ** Save £300 Save £200 Tel: +44 (0)20 7332 0881 Fax. +44 020 7332 0882 + Full access to conference c £2197 + VAT c £2297 + VAT c £2497 + VAT Email: enquire@cctvenues.co.uk recordings * ACCOMMODATION: Conference + 1 Workshop ** Save £200 Save £100 Hotel accommodation is not included in the conference fee. c £1798 + VAT c £1898 + VAT c £1998 + VAT To view accommodation nearby please visit www.cctvenues.co.uk/cw_hotels.htm or www.4cityhotels.com Conference + Full Access Save £200 Save £100 to Conference Recordings* c £1798 + VAT c £1898 + VAT c £1998 + VAT DIGITAL CONFERENCE ON CD ROM Save £100 A digital version of the conference proceedings, including all Conference Only c £1399 + VAT c £1499 + VAT c £1499 + VAT presentations, is available to buy. c I cannot attend the event, please send me the CD Rom priced at £599 plus VAT * Tick this Box if you Wish to Opt Out of Full Access to Conference Recordings (Reducing Price by £499) c Recent digital conferences available - £599 plus VAT each ** Please select choice of workshop A c B c or C c *** To qualify for discounts, payments must be received by the early bird registration deadline. Early booking discounts are not valid in conjunction c Compound Management with any other offer. c Improving Solubility for Pharmaceuticals and Biologics All above prices are subject to UK VAT at 17.5%. VAT Reg# GB 799 2259 67 c Polymorphism and Crystallisation c Clinically Relevant Drug Transporters Delegate Information c Pharmaceutical Co-Crystals 2010 c Amorphous Pharmaceutical Materials 2010 c Please send me conference materials indicated above. DELEGATE cMr cMrs cMiss cMs cDr cOther c I have filled out credit card details opposite. First Name For further information Please call: 0207 368 9300 or email: knowledgebank@iqpc.co.uk. Family Name To search IQPC’s archived conference documentation visit:www.iqpcknowledgebank.com Position Email Organisation TERMS CONDITIONS Please read the information listed below as each booking is subject to IQPC Ltd Address standard terms and conditions. Payment terms: Upon completion and return of the registration form, full Tel Fax payment is required no later than 5 business days from the date of invoice. Payment of invoices by means other than by credit card, or purchase order (UK Approving Manager Plc and UK government bodies only) will be subject to a £49 (plus VAT) per delegate processing fee. Payment must be received prior to the conference date. We reserve the right to refuse admission to the conference if payment has not been received. Signature IQPC Cancellation, Postponement and Substitution Policy: You I agree to IQPC’s cancellation and payment terms may substitute delegates at any time by providing reasonable advance notice to IQPC. For any cancellations received in writing not less than eight (8) days prior to the conference, you will receive a 90% credit to be used at another IQPC conference which must occur within one year from the date of issuance of such credit. An administration fee of 10% of the contract fee will be retained by IQPC for all permitted cancellations. No credit will be issued for any cancellations Payment Methods Total price for your organisation (Add total of all individuals attending): occurring within seven (7) days (inclusive) of the conference. In the event that IQPC cancels an event for any reason, you will receive a credit for 100% of the contract fee paid. You may use this credit for another IQPC event to be mutually agreed Card Type: VISAc c c M/C AMEX with IQPC, which must occur within one year from the date of cancellation. In the event that IQPC postpones an event for any reason and the delegate is unable or unwilling to attend in on the rescheduled date, you will receive a credit for 100% Card Number: cccccccccccccccc of the contract fee paid. You may use this credit for another IQPC event to be mutually agreed with IQPC, which must occur within one year from the date of postponement. Except as specified above, no credits will be issued for cancellations. There are no refunds given under any circumstances. IQPC is not responsible Exp. Date: cccc cccc Sec: for any loss or damage as a result of a substitution, alteration or cancellation/ postponement of an event. IQPC shall assume no liability whatsoever in the event this conference is cancelled, rescheduled or postponed due to a fortuitous event, Act of God, unforeseen occurrence or any other event that renders performance Name On Card: Signature: of this conference impracticable, illegal or impossible. For purposes of this clause, a fortuitous event shall include, but not be limited to: war, fire, labour strike, extreme weather or other emergency. Please note that while speakers and topics Billing Address (if different from above): Conference Code: 19003.001 were confirmed at the time of publishing, circumstances beyond the control of the organizers may necessitate substitutions, alterations or cancellations of the speakers and/or topics. As such, IQPC reserves the right to alter or modify the advertised speakers and/or topics if necessary without any liability to you City/County/Postcode whatsoever. Any substitutions or alterations will be updated on our web page as soon as possible. Cheque enclosed for: £ Discounts: All ‘Early Bird’ Discounts require payment at time of registration and before the cut-off date in order to receive any discount. Any discounts offered (Made payable to IQPC Ltd.) whether by IQPC (including team discounts) must also require payment at the time By Direct Transfer: IQPC Bank Details: HSBC Bank, 67 George Street, Richmond, Surrey, TW9 1HG of registration. All discount offers cannot be combined with any other offer. Account No: 51304143 Account Name: IQPC Ltd IBAN No: GB59 MIDL 4038 1851 3041 43 Data protection: Personal data is gathered in accordance with the Data Sort Code: 40 38 18 Swift Code: MIDLGB2112V Ref: Please include name of the attendee(s) and the conference code 19003.001 Protection Act 1998. Your details may be passed to other companies who wish to communicate with you offers related to your business activities. If you do not wish to receive these offers, please tick the box below. Please do not pass my information to any third party c PAYMENT MUST BE RECEIVED PRIOR TO THE CONFERENCE ©IQPC Ltd. 2010 UK VAT registration no. GB 799 2259 67